Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541664 | 0.92 | PTGS1 (0.51) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL10823820 | 0.88 | CYP3A4 (0.51) | PTGS1PTGS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL71414 | 0.83 | PTGS1 (0.62) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL3669879 | 0.80 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL20559648 | 0.80 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL25066870 | 0.80 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL14376154 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL1744600 | 0.80 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL17541509 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL19287601 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| US-20230120169-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2023-04-20 | — | — | US | disclosed |
| CN-109071526-B | Acid addition salts of piperazine derivatives | 阿森纽荣股份公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2023-02-28 | — | — | US | disclosed |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2023-02-28 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3419974-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-3186243-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120169-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | DNPEP, GAA, SLC30A5 | PTGS1 895/4885PTGS2 968/4885AOC3 884/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | PTGS1 4288/4885PTGS2 4499/4885AOC3 1626/4885 |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | PTGS1 895/4885PTGS2 968/4885AOC3 884/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | PTGS1 4288/4885PTGS2 4499/4885AOC3 1626/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | PTGS1 4288/4885PTGS2 4499/4885AOC3 1626/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | PTGS1 895/4885PTGS2 968/4885AOC3 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.